All Translational Science articles – Page 30
-
ArticleThe rising impact of biomarkers in early clinical development
Dr Cyril Clarke at ICON Biotech reveals how biomarkers are transforming early-phase clinical trials by offering valuable insights into the safety and efficacy of novel therapies.
-
ArticleAdvancements in hit identification for membrane protein drug discovery
GPCRs are crucial drug targets, but their complex structures present significant challenges in drug discovery. In this article, Domainex’s Philip Rawlins explores how fragment-based screening and innovative technologies like PoLiPa are helping to overcome these hurdles, with a focus on the Adenosine A2a receptor.
-
ArticleNext-gen biotech: rBIO’s approach to affordable insulin solutions
rBIO is transforming the biosimilar insulin market with a novel biomanufacturing platform designed to reduce production costs while maintaining high-quality standards. CEO Cameron Owen shares how their approach is shaping drug discovery and improving patient access to life-saving treatments.
-
NewsNew melanoma therapy prevents brain metastasis in preclinical studies
A government-funded research team has identified focal adhesion kinase (FAK) as a key driver of melanoma metastasis to the brain. This discovery could revolutionise treatment by not only addressing the condition but also preventing its spread to the brain.
-
ArticleGene silencing: a step forward for rare disease therapy
Gene silencing offers a promising approach to treating rare neurological diseases like H-ABC. With clinical trials on the horizon, find out how targeted therapies could bring real hope to patients and families.
-
NewsTract Bio identifies drug targets for oesophageal cancer
Tract Bio’s new research reveals key insights into the evolution of oesophageal adenocarcinoma (EAC) and identifies promising drug combinations for more effective treatment.
-
ArticleNew advances in hormone replacement therapy set to transform care
Hormone replacement therapy has long been used to treat low hormone levels, but existing delivery methods struggle with poor adherence and inconsistent hormone delivery. Lisa Stehno-Bittel of Likarda and Charles Virden of VitalTE discuss a novel approach using hormone-filled microbeads in hydrogels for steady, extended release after monthly self-injections.
-
ArticleWhy DNA Damage Response deserves renewed focus in cancer therapy
As cancer therapies evolve, a critical opportunity is emerging in the form of DNA Damage Response (DDR) research. With breakthroughs in genomics, drug delivery and AI, DDR pathways are set to overcome resistance and alter treatment strategies. Find out why now is the perfect moment to refocus on DDR, and ...
-
NewsNovel radioactive drug targets aggressive metastatic melanoma
Scientists in Japan have developed a new radioactive drug that emits alpha particles, showing promise for targeting metastatic melanoma - an aggressive skin cancer resistant to many conventional treatments.
-
ArticleThe evolution of AI in drug discovery: learning from history's mistakes (Part 2)
In this second part of a two-part series, we continue Sujeegar Jeevanandam’s exploration of the future of AI in drug discovery. We share his vision for transformative AI applications, such as simulating human pharmacokinetics and pharmacodynamics, and offer strategic recommendations for biotechs looking to adopt AI.
-
NewsNew research offers hope for high-grade glioma treatment
High-grade glioma, an aggressive brain cancer affecting both paediatric and adult patients, remains difficult to treat. A collaborative study from the University of Michigan, Dana-Farber Cancer Institute, and the Medical University of Vienna reveals a promising new treatment approach.
-
ReportBeyond the Lab: Artificial Intelligence
Download our latest report to discover how AI is transforming drug discovery, accelerating treatments and driving personalised care.
-
NewsNanoparticle therapy shows potential to prevent spread of pancreatic cancer to liver
Pancreatic cancer is notoriously hard to treat, especially when it spreads to the liver in advanced stages. Researchers at UCLA’s California NanoSystems Institute (CNSI) have developed an innovative nanoparticle technology to tackle this challenge.
-
NewsCeSPIACE: New peptide drug blocks COVID-19 variants
Scientists have developed CeSPIACE, a peptide drug that offers broad protection against COVID-19 variants, including Omicron XBB.1.5. Find out how it targets a stable part of the virus’s spike protein, making it resistant to mutations.
-
ArticleAbelacimab: the next frontier in safer anticoagulation therapy
Abelacimab represents a breakthrough in drug discovery, offering a novel approach to anticoagulation that could potentially prevent strokes with minimal bleeding risk. Learn how this innovative treatment could set new standards for both clinical practice and pharmaceutical research.
-
ArticleFrom Yale to healthcare leader: Dr Shika Pappoe’s impact on kidney care
Dr Shika Pappoe’s journey from Yale and Harvard to transforming kidney care highlights how combining clinical expertise with innovation can reshape healthcare. Read on for her insights on overcoming challenges and driving change in STEM and patient care.
-
News
Scientists discover key to long COVID lung damage and potential treatment
Scientists at the University of Virginia (UVA) School of Medicine have uncovered a crucial mechanism behind the lingering effects of long COVID, revealing how severe COVID-19 infections impair immune cells’ ability to repair lung tissue.
-
ArticleThe future of mental health treatment: Zelquistinel's role
Learn about zelquistinel, an innovative NMDA receptor modulator that is transforming treatment possibilities through a novel approach to synaptic plasticity. This breakthrough drug offers new insights into early drug discovery and the future of neuropsychiatric treatment.
-
NewsFirst AI-designed drug, Rentosertib, officially named by USAN
Insilico Medicine’s AI-designed drug for idiopathic pulmonary fibrosis (IPF), Rentosertib, has been granted an official name by USAN. This is the first drug where both the target and compound were discovered using generative AI, marking a major milestone in AI-driven drug development.
-
ArticleThe evolution of AI in drug discovery: learning from history's mistakes (Part 1)
AI is transforming drug discovery, but its adoption mirrors past technological shifts in the industry. In this first part of a two-part series, we reveal Sujeegar Jeevanandam’s observations of the parallels between AI and the electronic lab notebook revolution, highlighting key challenges, lessons learned, and what the future holds for ...